Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: A French Society of Pediatric Oncology study

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4726-4734

  Oyharcabal Bourden, V ^a   Kalifa, C ^a   Gentet, J C ^a   Frappaz, D ^a   Edan, C ^a   Chastagner, P ^a   Sariban, E ^a   Pagnier, A ^a   Babin, A ^a   Pichon, F ^a   Neuenschwander, S ^a   Vinchon, M ^a   Bours, D ^a   Mosseri, V ^a   Le Gales, C ^a   Ruchoux, M ^a   Carrie, C ^a   Doz, François ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROXYUREA; METHYLPREDNISOLONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; HORMONE SUBSTITUTION; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDULLOBLASTOMA; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT FAILURE; ADJUVANT CHEMOTHERAPY; BRAIN; CEREBELLUM TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RADIATION EXPOSURE; SURVIVAL RATE; VERTEBRAL CANAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; CARBOPLATIN; CEREBELLAR NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; RADIOTHERAPY DOSAGE; SPINAL CANAL; SURVIVAL RATE;

EID: 23044468278     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.760     Document Type: Article

References (38)

1. Gnekow AK: Recommendations of the Brain Tumor Subcommittee for the reporting of trials: SIOP Brain Tumor Subcommittee-International Society of Pediatric Oncology. Med Pediatr Oncol 24:104-108, 1995
2. Kühl J, Doz F, Taylor R: Embryonic tumours, in Walker DPG, Punt J (eds): Central Nervous System Tumours in Childhood. London, United Kingdom, Arnold, 2003, pp 314-330
3. Hoppe-Hirsch E, Brunet L, Laroussinie F, et al: Intellectual outcome in children with malignant tumors of the posterior fossa: Influence of the field of irradiation and quality of surgery. Childs Nerv Syst 11:340-346, 1995
4. Duffner PK, Cohen ME, Thomas P: Late effects of treatment on the intelligence of children with posterior fossa tumors. Cancer 51: 233-237, 1983
5. Oberfield SE, Allen JC, Pollack J, et al: Long-term endocrine sequelae after treatment of medulloblastoma: Prospective study of growth and thyroid function. J Pediatr 108:219-223, 1986
6. Stubberfield TG, Byrne GC, Jones TW: Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood: 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 17:167-171, 1995
7. Waber DP, Shapiro BL, Carpentieri SC, et al: Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: A 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 92:15-22, 2001
8. Bailey CC, Gnekow A, Wellek S, et al: Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO)-SIOP II. Med Pediatr Oncol 25:166-178, 1995
9. Deutsch M, Thomas PR, Krischer J, et al: Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma: A combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 24:167-177, 1996
10. Thomas PR, Deutsch M, Kepner JL, et al: Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004-3011, 2000
11. Mulhern RK, Kepner JL, Thomas PR, et al: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 16:1723-1728, 1998
12. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17: 2127-2136, 1999
13. Ris MD, Packer R, Goldwein J, et al: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 19:3470-3476, 2001
14. Grill J, Renaux VK, Bulteau C, et al: Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 45: 137-145, 1999
15. Pendergrass TW, Milstein JM, Geyer JR, et al: Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 5:1221-1231, 1987
16. Chastagner P, Olive D, Philip T, et al: Efficacy of the "8 drugs in a day" protocol in brain tumors in children. Arch Fr Pediatr 45:249-254, 1988
17. Gentet JC, Bouffet E, Doz F, et al: Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: Results of the M7 French Cooperative Study. J Neurosurg 82:608-614, 1995
18. Gentet JC, Doz F, Bouffet E, et al: Carboplatin and VP 16 in medulloblastoma: A phase II study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 23:422-427, 1994
19. Feeny D, Furlong W, Boyle M, et al: Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 7:490-502, 1995
20. Le Gales C, Costet N, Gentet JC, et al: Cross-cultural adaptation of a health status classification system in children with cancer: First results of the French adaptation of the Health Utilities Index Marks 2 and 3. Int J Cancer Suppl 12:112-118, 1999
21. Carrie C, Hoffstetter S, Gomez F, et al: Impact of targeting deviations on outcome in medulloblastoma: Study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 45:435-439, 1999
22. Eberhart CG, Burger PC: Anaplasia and grading in medulloblastomas. Brain Pathol 13: 376-385, 2003
23. Tait DM, Thornton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26:464-469, 1990
24. Evans AE, Jenkin RD, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572-582, 1990
25. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591, 2003
26. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
27. Thiesse P, Jaspan T, Couanet D, et al: A protocol for imaging pediatric brain tumors. J Radiol 82:11-16, 2001
28. Fouladi M, Gajjar A, Boyett JM, et al: Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 17:3234-3237, 1999
29. Kortmann RD, Kuhl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
30. Brand WN, Schneider PA, Tokars RP: Long-term results of a pilot study of low dose cranial-spinal irradiation for cerebellar medulloblastoma. Int J Radiat Oncol Biol Phys 13:1641-1645, 1987
31. Halberg FE, Wara WM, Fippin LF, et al: Low-dose craniospinal radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 20: 651-654, 1991
32. Levin VA, Rodriguez LA, Edwards MS, et al: Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. J Neurosurg 68:383-387, 1988
33. Hughes EN, Shillito J, Sallan SE, et al: Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984: The influence of radiation dose on the patterns of failure and survival. Cancer 61:1992-1998, 1988
34. Packer RJ, Gajjar R, Vezina G, et al: Preliminary results of a prospective randomized study of "reduced" craniospinal radiotherapy followed by one of two adjuvant chemotherapy regimens for children with medulloblastoma: Children's Oncology Group study. Ann Neurol 56:s89-s90, 2004 (suppl 8)
35. Mulhern RK: Correlation of the Health Utilities Index Mark 2 cognition scale and neuropsychological functioning among survivors of childhood medulloblastoma. Int J Cancer Suppl 12:91-94, 1999
36. Palmer SL, Goloubeva O, Reddick WE, et al: Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308, 2001
37. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-993, 2004
38. Fernandez-Teijeiro A, Betensky RA, Sturla LM, et al: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22:994-998, 2004